Sg3 Management, LLC Regeneron Pharmaceuticals, Inc. Call Options Transaction History

Sg3 Management, LLC

12 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2023 May 15, 2023	SELL	$680.49 - $826.97 $3.33 Million - $4.05 Million	-4,900 Closed	0 $0
Q3 2022 May 15, 2023	BUY	$573.97 - $724.32 $2.81 Million - $3.55 Million	4,900 New	4,900 $3.38 Million
Q3 2022 Nov 14, 2022	BUY	$573.97 - $724.32 $2.81 Million - $3.55 Million	4,900 New	4,900 $3.38 Million
Q1 2021 May 17, 2021	BUY	$446.73 - $548.2 $7.82 Million - $9.59 Million	17,500 Added 700.0%	20,000 $9.46 Million
Q4 2020 Feb 16, 2021	BUY	$478.3 - $607.98 $1.2 Million - $1.52 Million	2,500 New	2,500 $1.21 Million
Q1 2018 May 11, 2018	SELL	$315.82 - $393.78 $473,730 - $590,670	-1,500 Closed	0 $0
Q4 2017 Feb 26, 2018	BUY	$358.63 - $469.95 $532,565 - $697,875	1,485 Added 9900.0%	1,500 $564,000
Q4 2017 Feb 13, 2018	SELL	$358.63 - $469.95 $532,565 - $697,875	-1,485 Reduced 99.0%	15 $0
Q3 2017 Feb 26, 2018	BUY	$431.38 - $504.0 $640,599 - $748,440	1,485 Added 9900.0%	1,500 $671,000
Q3 2017 Jan 25, 2018	SELL	$431.38 - $504.0 $640,599 - $748,440	-1,485 Reduced 99.0%	15 $10,000
Q2 2017 Feb 26, 2018	BUY	N/A	1,485 Added 9900.0%	1,500 $737,000
Q2 2017 Jan 25, 2018	BUY	N/A	15	15 $55,000

1,484

83.7M

1.22M

1.5M

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $76.1B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

Get notified when there are updates to the investment portfolio of Sg3 Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sg3 Management, LLC with notifications on news.